{"protocolSection": {"identificationModule": {"nctId": "NCT01211197", "orgStudyIdInfo": {"id": "1276.5"}, "secondaryIdInfos": [{"id": "2010-018589-22", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability", "officialTitle": "Relative Bioavailability of a 12.5 mg BI 10773 / 1000 mg Metformin Fixed Dose Combination Tablet Compared With Its Monocomponents and Administered With and Without Food (an Open-label, Randomised, Single-dose, Three-way Crossover, Phase I Trial in Healthy Volunteers)"}, "statusModule": {"statusVerifiedDate": "2015-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-10"}, "primaryCompletionDateStruct": {"date": "2010-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-09-28", "studyFirstSubmitQcDate": "2010-09-28", "studyFirstPostDateStruct": {"date": "2010-09-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-06-26", "resultsFirstSubmitQcDate": "2015-07-27", "resultsFirstPostDateStruct": {"date": "2015-08-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-07-27", "lastUpdatePostDateStruct": {"date": "2015-08-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The objective of the current study is to determine the relative bioavailability of a BI 10773 / metformin fixed dose combination tablet compared to single tablets of BI 10773 and metformin when administered together and to assess the effect of food on the bioavailability the fixed dose combination tablet"}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 16, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "A", "type": "EXPERIMENTAL", "description": "3 treatments will be investigated in randomized order", "interventionNames": ["Drug: A: BI 10773 / metformin tablet"]}, {"label": "B", "type": "EXPERIMENTAL", "description": "3 treatments will be investigated in randomized order", "interventionNames": ["Drug: B: BI 10773 tablet and metformin tablet"]}, {"label": "C", "type": "EXPERIMENTAL", "description": "3 treatments will be investigated in randomized order", "interventionNames": ["Drug: C: BI 10773 / metformin tablet"]}], "interventions": [{"type": "DRUG", "name": "C: BI 10773 / metformin tablet", "description": "BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal", "armGroupLabels": ["C"]}, {"type": "DRUG", "name": "B: BI 10773 tablet and metformin tablet", "description": "BI 10773 and metformin single tablets, administered together in fasted state", "armGroupLabels": ["B"]}, {"type": "DRUG", "name": "A: BI 10773 / metformin tablet", "description": "BI 10773 / metformin fixed dose combination tablet in fasted state", "armGroupLabels": ["A"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Empa: Area Under the Curve 0 to Infinity (AUC0-\u221e)", "description": "Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.\n\nNote the standard deviation is actually the coefficient of variation (CV).", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Empa: Maximum Measured Concentration (Cmax)", "description": "Maximum measured concentration of empagliflozin (empa) in plasma.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Metformin: Area Under the Curve 0 to Infinity (AUC0-\u221e)", "description": "Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Metformin: Maximum Measured Concentration (Cmax)", "description": "Maximum measured concentration of metformin in plasma.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}], "secondaryOutcomes": [{"measure": "Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)", "description": "Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Metformin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)", "description": "Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable data point.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Time to Maximum Measured Concentration (Tmax)", "description": "Time from dosing to the maximum concentration of the analyte in plasma.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Terminal Elimination Rate Constant in Plasma (\u03bbz)", "description": "Terminal elimination rate constant in plasma.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Terminal Half-life in Plasma (T1/2)", "description": "Terminal half-life of the analyte in plasma.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Mean Residence Time in the Body After Oral Administration (MRTpo)", "description": "Mean residence time of the analyte in the body after oral administration.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Apparent Clearance After Extravascular Administration (CL/F)", "description": "Apparent clearance of the analyte in the plasma after extravascular administration.\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Apparent Volume of Distribution During the Terminal Phase (Vz/F)", "description": "Apparent volume of distribution during the terminal phase (\u03bbz).\n\nNote the standard deviation is actually the CV.", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration"}, {"measure": "Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.", "description": "Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment of tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as adverse events.", "timeFrame": "Drug administration up to 7 days after last drug administration, up to 8 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Healthy males and females according to the following criteria\n2. Body Mass Index 18.5 to 29.9 kg/m2 (incl.)\n\nExclusion criteria:\n\n1. Any finding of the medical examination (including Blood Pressure, Pulse Rate and electrocardiogram) deviating from normal and of clinical relevance\n2. Any evidence of a clinically relevant concomitant disease", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1276.5.1 Boehringer Ingelheim Investigational Site", "city": "Biberach", "country": "Germany", "geoPoint": {"lat": 48.09345, "lon": 9.79053}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "An open label, randomised, three-way crossover study. A washout period of at least 7 days was respected between drug administrations.", "groups": [{"id": "FG000", "title": "FDC Fasted / Individual Tablets Fasted / FDC Fed", "description": "Patients received the three treatments in the following order:\n\n* FDC tablet, containing 12.5mg empagliflozin (BI 10773) and 1000mg metformin, under fasted conditions\n* 12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions"}, {"id": "FG001", "title": "FDC Fasted / FDC Fed / Individual Tablets Fasted", "description": "Patients received the three treatments in the following order:\n\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions\n* 12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions"}, {"id": "FG002", "title": "Individual Tablets Fasted / FDC Fasted / FDC Fed", "description": "Patients received the three treatments in the following order:\n\n* 12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions"}, {"id": "FG003", "title": "Individual Tablets Fasted / FDC Fed / FDC Fasted", "description": "Patients received the three treatments in the following order:\n\n* 12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions"}, {"id": "FG004", "title": "FDC Fed / FDC Fasted / Individual Tablets Fasted", "description": "Patients received the three treatments in the following order:\n\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions\n* 12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions"}, {"id": "FG005", "title": "FDC Fed / Individual Tablets Fasted / FDC Fasted", "description": "Patients received the three treatments in the following order:\n\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions\n* 12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions\n* FDC tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions"}], "periods": [{"title": "Treatment Period 1 (1 Day)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Washout Period 1 (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Treatment Period 2 (1 Day)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Washout Period 2 (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Treatment Period 3 (1 Day)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Study Overall", "description": "An open label, randomised, three-way crossover study. The three treatments administered were\n\n* Fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions\n* 12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions\n* Fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions\n\nA washout period of at least 7 days was respected between drug administrations."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "35.8", "spread": "7.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Empa: Area Under the Curve 0 to Infinity (AUC0-\u221e)", "description": "Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.\n\nNote the standard deviation is actually the coefficient of variation (CV).", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nmol*h/L", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2920", "spread": "16.2"}, {"groupId": "OG001", "value": "2860", "spread": "18.5"}, {"groupId": "OG002", "value": "2710", "spread": "15.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Ratio calculated as FDC fasted divided by individual tablets fasted.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "100.59", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "95.75", "ciUpperLimit": "105.67", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "7.6", "estimateComment": "Standard deviation is actually the intra-individual geometric coefficient of variation (gCV)."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Ratio calculated as FDC fed divided by FDC fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "94.94", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "89.85", "ciUpperLimit": "100.33", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "8.0", "estimateComment": "Standard deviation is actually the intra-individual gCV."}]}, {"type": "PRIMARY", "title": "Empa: Maximum Measured Concentration (Cmax)", "description": "Maximum measured concentration of empagliflozin (empa) in plasma.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nmol/L", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "404", "spread": "17.4"}, {"groupId": "OG001", "value": "405", "spread": "15.8"}, {"groupId": "OG002", "value": "259", "spread": "20.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Ratio calculated as FDC fasted divided by individual tablets fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "99.31", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.76", "ciUpperLimit": "107.49", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "12.2", "estimateComment": "Standard deviation is actually the intra-individual gCV."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Ratio calculated as FDC fed divided by FDC fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "64.30", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "55.97", "ciUpperLimit": "73.87", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "20.6", "estimateComment": "Standard deviation is actually the intra-individual gCV."}]}, {"type": "SECONDARY", "title": "Empa: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)", "description": "Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nmol*h/L", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2860", "spread": "16.3"}, {"groupId": "OG001", "value": "2800", "spread": "18.6"}, {"groupId": "OG002", "value": "2640", "spread": "15.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Ratio calculated as FDC fasted divided by individual tablets fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "100.94", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.03", "ciUpperLimit": "106.11", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "7.7", "estimateComment": "Standard deviation is actually the intra-individual gCV."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Ratio calculated as FDC fed divided by FDC fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "94.39", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "89.22", "ciUpperLimit": "99.87", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "8.2", "estimateComment": "Standard deviation is actually the intra-individual gCV."}]}, {"type": "SECONDARY", "title": "Metformin: Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)", "description": "Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable data point.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9900", "spread": "17.9"}, {"groupId": "OG001", "value": "9720", "spread": "22.3"}, {"groupId": "OG002", "value": "9550", "spread": "19.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Ratio calculated as FDC fasted divided by individual tablets fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "103.13", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "95.59", "ciUpperLimit": "111.25", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "11.7", "estimateComment": "Standard deviation is actually the intra-individual gCV."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Ratio calculated as FDC fed divided by FDC fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "96.96", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "87.23", "ciUpperLimit": "107.78", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "15.5", "estimateComment": "Standard deviation is actually the intra-individual gCV."}]}, {"type": "PRIMARY", "title": "Metformin: Area Under the Curve 0 to Infinity (AUC0-\u221e)", "description": "Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10300", "spread": "16.9"}, {"groupId": "OG001", "value": "10100", "spread": "21.2"}, {"groupId": "OG002", "value": "10200", "spread": "15.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Ratio calculated as FDC fasted divided by individual tablets fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "102.15", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.87", "ciUpperLimit": "111.15", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "13.0", "estimateComment": "Standard deviation is actually the intra-individual gCV."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Ratio calculated as FDC fed divided by FDC fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "100.67", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.70", "ciUpperLimit": "110.51", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "13.7", "estimateComment": "Standard deviation is actually the intra-individual gCV."}]}, {"type": "PRIMARY", "title": "Metformin: Maximum Measured Concentration (Cmax)", "description": "Maximum measured concentration of metformin in plasma.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1550", "spread": "19.1"}, {"groupId": "OG001", "value": "1530", "spread": "23.4"}, {"groupId": "OG002", "value": "1180", "spread": "25.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Ratio calculated as FDC fasted divided by individual tablets fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "103.49", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "95.30", "ciUpperLimit": "112.39", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "12.7", "estimateComment": "Standard deviation is actually the intra-individual gCV."}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Ratio calculated as FDC fed divided by FDC fasted", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "No formal testing, investigation of relative bioavailability.", "statisticalMethod": "ANOVA", "statisticalComment": "Based on ANOVA with terms for sequence, subjects within sequence, period and treatment", "paramType": "Geometric mean ratio", "paramValue": "75.13", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "63.68", "ciUpperLimit": "88.64", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "24.5", "estimateComment": "Standard deviation is actually the intra-individual gCV."}]}, {"type": "SECONDARY", "title": "Time to Maximum Measured Concentration (Tmax)", "description": "Time from dosing to the maximum concentration of the analyte in plasma.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"title": "Tmax of empagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.50", "spread": "34.2", "lowerLimit": "0.67", "upperLimit": "2.50"}, {"groupId": "OG001", "value": "1.75", "spread": "27.1", "lowerLimit": "1.00", "upperLimit": "2.50"}, {"groupId": "OG002", "value": "3.00", "spread": "54.6", "lowerLimit": "1.00", "upperLimit": "8.00"}]}]}, {"title": "Tmax of metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.50", "spread": "20.9", "lowerLimit": "2.00", "upperLimit": "4.00"}, {"groupId": "OG001", "value": "2.50", "spread": "26.3", "lowerLimit": "1.50", "upperLimit": "4.00"}, {"groupId": "OG002", "value": "3.00", "spread": "49.8", "lowerLimit": "1.50", "upperLimit": "8.00"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Elimination Rate Constant in Plasma (\u03bbz)", "description": "Terminal elimination rate constant in plasma.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "1/h", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"title": "\u03bbz of empagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0559", "spread": "43.9"}, {"groupId": "OG001", "value": "0.0601", "spread": "53.2"}, {"groupId": "OG002", "value": "0.0498", "spread": "46.6"}]}]}, {"title": "\u03bbz of metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0822", "spread": "73.3"}, {"groupId": "OG001", "value": "0.0756", "spread": "82.7"}, {"groupId": "OG002", "value": "0.0590", "spread": "108"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Half-life in Plasma (T1/2)", "description": "Terminal half-life of the analyte in plasma.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"title": "T1/2 of empagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.1", "spread": "46.6"}, {"groupId": "OG001", "value": "16.0", "spread": "61.3"}, {"groupId": "OG002", "value": "16.7", "spread": "43.0"}]}]}, {"title": "T1/2 of metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.6", "spread": "94.6"}, {"groupId": "OG001", "value": "17.8", "spread": "76.9"}, {"groupId": "OG002", "value": "30.5", "spread": "89.0"}]}]}]}, {"type": "SECONDARY", "title": "Mean Residence Time in the Body After Oral Administration (MRTpo)", "description": "Mean residence time of the analyte in the body after oral administration.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"title": "MRTpo of empagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.5", "spread": "17.6"}, {"groupId": "OG001", "value": "10.9", "spread": "25.1"}, {"groupId": "OG002", "value": "13.9", "spread": "23.0"}]}]}, {"title": "MRTpo of metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.53", "spread": "52.0"}, {"groupId": "OG001", "value": "10.2", "spread": "52.1"}, {"groupId": "OG002", "value": "19.4", "spread": "101"}]}]}]}, {"type": "SECONDARY", "title": "Apparent Clearance After Extravascular Administration (CL/F)", "description": "Apparent clearance of the analyte in the plasma after extravascular administration.\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/min", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"title": "CL/F of empagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "162", "spread": "15.0"}, {"groupId": "OG001", "value": "166", "spread": "17.1"}, {"groupId": "OG002", "value": "174", "spread": "13.3"}]}]}, {"title": "CL/F of metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "1670", "spread": "20.2"}, {"groupId": "OG001", "value": "1730", "spread": "25.4"}, {"groupId": "OG002", "value": "1670", "spread": "18.8"}]}]}]}, {"type": "SECONDARY", "title": "Apparent Volume of Distribution During the Terminal Phase (Vz/F)", "description": "Apparent volume of distribution during the terminal phase (\u03bbz).\n\nNote the standard deviation is actually the CV.", "populationDescription": "Pharmacokinetic (PK) set included all evaluable subjects who took at least 1 dose of investigational medication, provided at least one observation for at least one primary PK endpoint without important protocol violations relevant to the evaluation of pharmacokinetics.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres", "timeFrame": "1 hour (h) before drug administration and 20 minutes (min), 40min, 1 h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"title": "Vz/F of empagliflozin", "categories": [{"measurements": [{"groupId": "OG000", "value": "210", "spread": "45.3"}, {"groupId": "OG001", "value": "222", "spread": "58.0"}, {"groupId": "OG002", "value": "250", "spread": "44.3"}]}]}, {"title": "Vz/F of metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "2410", "spread": "99.5"}, {"groupId": "OG001", "value": "2650", "spread": "86.0"}, {"groupId": "OG002", "value": "4670", "spread": "112"}]}]}]}, {"type": "SECONDARY", "title": "Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator.", "description": "Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment of tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as adverse events.", "populationDescription": "Treated set (TS) includes all subjects who took at least 1 dose of investigational medication and was used for safety analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Drug administration up to 7 days after last drug administration, up to 8 days", "groups": [{"id": "OG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions."}, {"id": "OG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions."}, {"id": "OG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Drug administration up to 7 days after last drug administration, up to 8 days", "eventGroups": [{"id": "EG000", "title": "FDC Fasted", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 2, "otherNumAtRisk": 15}, {"id": "EG001", "title": "Individual Tablets Fasted", "description": "12.5mg empa and 1000mg metformin individual-component tablets under fasted conditions.", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 6, "otherNumAtRisk": 16}, {"id": "EG002", "title": "FDC Fed", "description": "A single fixed dose combination (FDC) tablet, containing 12.5mg empagliflozin and 1000mg metformin, under fasted conditions.", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 8, "otherNumAtRisk": 14}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 14}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MEDDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000570240", "term": "Empagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M258082", "name": "Empagliflozin", "asFound": "Thalidomide", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}